SPDR S&P Biotech ETF ETF Prediction and Forecast [XBI]

AI-generated source summary

The video provides a technical analysis of the SPDR S&P Biotech ETF (XBI). Since August 12, 2025, the system ranked the ETF as hold or accumulate, with a score of 0. The ETF has gained nearly 10% since the initial recommendation, yielding an average return of 0.55% per day. The exchange-traded fund has broken through a strong upward trend. There is potential support at $94.01. According to fan theory, $100.33 is the next potential peak. The current 3-month trend indicates a potential 10.24% change, with a projected return ranging from 1.26% to 8.56%. A 12-month analysis indicates a projected change of -15.46%, with a potential range of -$44.59 to -$15.46. A stop-loss is set at $91.79. A general buy signal exist, however the open price are overvalued. This assessment has several positive signals but are downgraded.

AI-generated summary based on the source content.

Evidence and evaluation progress

1. Original source published

   06 Sept 2025, 03:57 UTC

   The analyst published the original source item.

2. First prediction resolved

   30 Sept 2025, 18:30 UTC

   The first evaluable outcome in this case reached a terminal result.

3. Case evaluation completed

   30 Sept 2025, 18:30 UTC

   All evaluable predictions in this case reached terminal outcomes.

4. Source recorded by Tahlil Plus

   18 May 2026, 20:23 UTC

   The public source was preserved as the evidence record for this case.

5. Market predictions extracted

   18 May 2026, 20:47 UTC

   1 eligible signal linked to this case.

6. Outcome tracking started

   02 Jul 2026, 02:15 UTC

   Tahlil Plus began monitoring the extracted predictions.